Traws Pharma Files Q2 2024 10-Q

TL;DR

Traws Pharma (fka Onconova) dropped its Q2 10-Q. Financials look standard, check for any new developments.

AI Summary

Traws Pharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Onconova Therapeutics, Inc., is in the pharmaceutical preparations industry. The filing includes financial data for the second quarter and first half of 2024, with comparative data from 2023. Key financial statement components like common stock, retained earnings, and additional paid-in capital are detailed.

Why It Matters

This filing provides investors and analysts with the latest financial performance and position of Traws Pharma, Inc., crucial for understanding the company's operational health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Traws Pharma faces inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this summary but are typical for the sector.

Key Numbers

• 2024 Q2 — Reporting Period (Financials for the second quarter of 2024 are presented.)
• 2023 — Comparative Period (Financial data from 2023 is included for comparison.)

Key Players & Entities

• Traws Pharma, Inc. (company) — Filer of the 10-Q
• Onconova Therapeutics, Inc. (company) — Former name of Traws Pharma, Inc.
• 20240630 (date) — End of the reporting period for the 10-Q
• 20240815 (date) — Filing date of the 10-Q

FAQ

Key Financial Figures

• $0.01 — he registrant's Common Stock, par value $0.01 per share, as of August 1, 2024 was 25,

Filing Documents

• tmb-20240630x10q.htm (10-Q) — 1323KB
• tmb-20240630xex31d1.htm (EX-31.1) — 10KB
• tmb-20240630xex31d2.htm (EX-31.2) — 10KB
• tmb-20240630xex32d1.htm (EX-32.1) — 6KB
• tmb-20240630xex32d2.htm (EX-32.2) — 6KB
• 0001558370-24-012279.txt ( ) — 5938KB
• tmb-20240630.xsd (EX-101.SCH) — 43KB
• tmb-20240630_cal.xml (EX-101.CAL) — 38KB
• tmb-20240630_def.xml (EX-101.DEF) — 179KB
• tmb-20240630_lab.xml (EX-101.LAB) — 393KB
• tmb-20240630_pre.xml (EX-101.PRE) — 303KB
• tmb-20240630x10q_htm.xml (XML) — 933KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' (Deficit) Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 34

Controls and Procedures

Item 4. Controls and Procedures 34

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 35

Risk Factors

Item 1A. Risk Factors 35

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 38

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 38

Other Information

Item 5. Other Information 38

Exhibits

Item 6. Exhibits 39

SIGNATURES

SIGNATURES 40 2 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Traws Pharma, Inc. Condensed Consolidated Balance Sheets (unaudited) June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 16,886,000 $ 20,821,000 Receivables 18,000 18,000 Prepaid expenses and other current assets 1,767,000 1,821,000 Total current assets 18,671,000 22,660,000 Property and equipment, net 14,000 22,000 Other non-current assets 1,000 1,000 Total assets $ 18,686,000 $ 22,683,000 Liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity Current liabilities: Accounts payable $ 6,174,000 $ 5,619,000 Accrued expenses and other current liabilities 3,509,000 3,375,000 Deferred revenue 227,000 226,000 Total current liabilities 9,910,000 9,220,000 Deferred revenue, non-current 2,677,000 2,791,000 Total liabilities 12,587,000 12,011,000 Commitments and contingencies Series C redeemable convertible preferred stock; $ 0.01 par value, 5,000,000 shares authorized; 12,472 and zero shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 111,619,000 — Stockholders' (deficit) equity: Common stock, $ 0.01 par value, 125,000,000 shares authorized, 25,306,509 and 21,003,409 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 253,000 210,000 Additional paid in capital 505,017,000 493,116,000 Accumulated deficit ( 610,757,000 ) ( 482,631,000 ) Accumulated other comprehensive loss ( 33,000 ) ( 23,000 ) Total stockholders' (deficit) equity ( 105,520,000 ) 10,672,000 Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity $ 18,686,000 $ 22,683,000 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents Traws Pharma, Inc. Condensed Consolidated Statements of Operations (unaudited) Three Months Ended June 30, Six Months Ended June

View Full Filing

View this 10-Q filing on SEC EDGAR